FDA approves Winlevi for acne treatment
The FDA approved Winlevi for the treatment of acne, Cassiopea announced in a press release.
Winlevi (clascoterone cream 1%) is a topical androgen receptor inhibitor that limits hormones from increasing sebum production and inflammation.
“This milestone approval marks the introduction of a new class of topical medication in dermatology. Dermatologists have said targeting androgen hormonal activity in the skin is ‘the holy grail’ of acne treatment for both males and females,” Cassiopea CEO Diana Harbort said in the release.
The treatment is approved for use in patients aged 12 years and older and is expected to be available in the United States in early 2021.